Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, Minnesota.
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.
Cancer Res. 2024 Jun 14;84(12):2021-2033. doi: 10.1158/0008-5472.CAN-23-3005.
Single-cell RNA sequencing (scRNA-seq) greatly advanced the understanding of intratumoral heterogeneity by identifying distinct cancer cell subpopulations. However, translating biological differences into treatment strategies is challenging due to a lack of tools to facilitate efficient drug discovery that tackles heterogeneous tumors. Developing such approaches requires accurate prediction of drug response at the single-cell level to offer therapeutic options to specific cell subpopulations. Here, we developed a transparent computational framework (nicknamed scIDUC) to predict therapeutic efficacies on an individual cell basis by integrating single-cell transcriptomic profiles with large, data-rich pan-cancer cell line screening data sets. This method achieved high accuracy in separating cells into their correct cellular drug response statuses. In three distinct prospective tests covering different diseases (rhabdomyosarcoma, pancreatic ductal adenocarcinoma, and castration-resistant prostate cancer), the predicted results using scIDUC were accurate and mirrored biological expectations. In the first two tests, the framework identified drugs for cell subpopulations that were resistant to standard-of-care (SOC) therapies due to intrinsic resistance or tumor microenvironmental effects, and the results showed high consistency with experimental findings from the original studies. In the third test using newly generated SOC therapy-resistant cell lines, scIDUC identified efficacious drugs for the resistant line, and the predictions were validated with in vitro experiments. Together, this study demonstrates the potential of scIDUC to quickly translate scRNA-seq data into drug responses for individual cells, displaying the potential as a tool to improve the treatment of heterogenous tumors.
A versatile method that infers cell-level drug response in scRNA-seq data facilitates the development of therapeutic strategies to target heterogeneous subpopulations within a tumor and address issues such as treatment failure and resistance.
单细胞 RNA 测序 (scRNA-seq) 通过鉴定不同的癌细胞亚群,极大地提高了对肿瘤内异质性的认识。然而,由于缺乏促进有效药物发现的工具,将这些生物学差异转化为治疗策略具有挑战性,而这些工具可以解决异质肿瘤的问题。开发这种方法需要在单细胞水平上准确预测药物反应,为特定的细胞亚群提供治疗选择。在这里,我们开发了一种透明的计算框架(名为 scIDUC),通过将单细胞转录组谱与大型、富含数据的泛癌症细胞系筛选数据集相结合,在单细胞基础上预测药物疗效。该方法在将细胞正确分类到其正确的细胞药物反应状态方面具有很高的准确性。在涵盖不同疾病(横纹肌肉瘤、胰腺导管腺癌和去势抵抗性前列腺癌)的三个独立前瞻性测试中,使用 scIDUC 预测的结果是准确的,反映了生物学预期。在前两个测试中,该框架确定了对标准治疗(SOC)疗法具有内在耐药性或肿瘤微环境效应的细胞亚群的药物,结果与原始研究中的实验结果高度一致。在第三个使用新产生的 SOC 耐药细胞系的测试中,scIDUC 确定了对耐药系有效的药物,并且通过体外实验验证了预测。总之,这项研究表明,scIDUC 有可能将 scRNA-seq 数据快速转化为个体细胞的药物反应,有望成为改善异质肿瘤治疗的工具。
一种推断 scRNA-seq 数据中细胞水平药物反应的多功能方法,有助于开发针对肿瘤内异质亚群的治疗策略,并解决治疗失败和耐药等问题。